FDA Proposes Rule to Close Registration Gap for Foreign Drug Manufacturers

The U.S. Food and Drug Administration (FDA) has proposed a rule that would close a long-standing registration gap for foreign drug manufacturers, while also simplifying how distributed manufacturing networks register domestically. If finalized, the rule would affect both foreign establishments producing drugs or drug components for indirect export to the U.S. and companies operating multi-site hub-and-spoke manufacturing models. 

The proposal touches two distinct groups within the drug supply chain. Foreign manufacturers producing active pharmaceutical ingredients or other drug components who have historically fallen outside FDA registration requirements would face new obligations, while companies running distributed manufacturing networks would gain a simpler path to registering multiple production sites as a single establishment. Both changes reflect the FDA’s stated interest in strengthening its visibility into where and how drugs sold in the U.S. are actually made. 

Closing the Foreign Establishment Registration Gap 

Under current FDA regulations, foreign establishments that manufacture drugs, including active pharmaceutical ingredients (APIs), are not always required to register if they distribute exclusively to other foreign establishments rather than directly to the U.S. market. This has left a visibility gap for the FDA when those drugs or components eventually enter the U.S. supply chain indirectly, often several steps removed from the original manufacturer. 

The proposed rule would align FDA regulations more closely with existing statutory registration requirements, making clear that these foreign establishments must register and report on the drugs they produce. According to the FDA, the change is intended to give the agency a clearer ability to trace where an active ingredient in a U.S. medicine originated, and to detect and respond to potential safety concerns earlier in the supply chain. 

For foreign manufacturers who have historically operated outside FDA’s registration requirements because their drugs or components reached the U.S. only indirectly, this proposal represents a meaningful shift. Companies in this position may want to review their current registration status and supply chain relationships to understand whether they would fall within the expanded scope if the rule is finalized as proposed. 

Streamlining Registration for Distributed Manufacturing Networks 

The proposed rule would also change how distributed manufacturing establishments register in the U.S. These are companies that operate multiple equivalent manufacturing units at different physical locations, coordinated through a central quality oversight hub, commonly described as a hub-and-spoke model. 

Under the current framework, each manufacturing unit in a distributed network must register separately with the FDA, which the agency has acknowledged creates administrative burden without necessarily improving oversight. The proposed rule would allow distributed manufacturing establishments to register as a single establishment, with a streamlined process for adding, relocating, or removing individual units. Companies would be required to notify the FDA in advance of any unit relocation, which the agency says would close a gap in its ability to maintain real-time visibility into where manufacturing is occurring. 

The FDA has stated that, if finalized, this change is expected to reduce registration costs for distributed manufacturing companies and create efficiencies for both industry and the agency. 

Why the FDA Is Proposing These Changes 

Both provisions are part of a broader effort the FDA describes as strengthening oversight of the U.S. drug supply chain and reducing vulnerabilities within it. The agency has framed the proposal as part of a coordinated set of actions aimed at supporting domestic pharmaceutical manufacturing and improving supply chain transparency, rather than as a standalone or isolated update. 

What This Means for Your Business 

Since this is a proposed rule rather than a final one, no registration requirements have changed yet, and the FDA has not set an implementation date. As with any proposed rule published for notice and comment, the requirements described here could be modified before finalization based on stakeholder input. 

That said, companies with foreign manufacturing relationships, particularly those producing APIs or other drug components for indirect distribution into the U.S. market, may find it useful to start mapping their current registration status against the proposed scope now. This is especially relevant for companies that rely on a U.S. Agent to manage FDA communications and registration on their behalf, since expanded registration obligations would likely increase the role that representation plays in maintaining compliance. 

Companies operating distributed manufacturing networks may also want to evaluate whether consolidating registration under a single establishment, once available, would simplify their current compliance workflow.